(MENAFN- Kashmir Observer)
London: The scientific body overseeing Britain's coronavirus vaccination programme on Friday recommended that under-40s are offered an alternative to the Oxford-AstraZeneca Covid jab.
The Joint Committee on Vaccination and Immunisation (JCVI) said it was taking the "precautionary approach" for adults aged 30-39, after assessment of blood clot risks.
Professor Wei Shen Lim of the JCVI advisory committee said that those aged 30-39 will be "preferentially offered an alternative to the AstraZeneca vaccine".
This will happen as long as an alternative is available and does not create a substantial delay in vaccination, and as long as the UK keeps the virus situation under control, he added.
Lim said the aim was to "further increase vaccine confidence" as under-40s are due to be vaccinated soon, by showing that the government is putting a "high priority on safety".
The UK — which launched a mass vaccination drive in December last year with the Pfizer-BioNTech shot — is still on track to give all adults a first vaccine dose by the end of July, Lim said.
Thank you for connecting with us. We will respond to you shortly.
BE PART OF QUALITY JOURNALISM
11https://kashmirobserver.net/wp-content/plugins/nex-formsfalsehttps://kashmirobserver.net/support-our-journalism/redirecthttps://kashmirobserver.net/wp-admin/admin-ajax.phphttps://kashmirobserver.net/2021/05/07/uk-advises-under-40s-get-alternative-to-astrazeneca-covid-vaccineyes1fadeInfadeOut Subscribe Now for NewsletterSubmit
He added that the success of the vaccine rollout means that "a future wave of infection is likely to be smaller than anticipated".
June Raine, who heads the UK's Medicines and Healthcare products Regulatory Agency, said it was not changing its advice on the AstraZeneca vaccine as side effects were "extremely rare".
From more than 28 million first doses of the vaccine administered in the UK by April 28, there were 242 cases reported of clots combined with low blood platelet levels, or 10.5 per million, said Raine.
These clots occurred in 141 women and 100 men aged from 18 to 93, and the overall case death rate was 20 percent, with 49 deaths.
‘Finely balanced'
Six cases have been reported after a second dose of the vaccine.
Raine said this meant that the benefits of the AstraZeneca vaccine still outweigh the risks of coronavirus for the vast majority of people.
For younger people, this ratio is "more finely balanced", she said, however.
Nearly 128,000 people have died from the coronavirus in the UK, the highest figure in Europe.
The UK has now administered nearly 35 million first doses of vaccine and more than 16 million second doses.
A government spokesman said it would follow the advice, adding: "The Oxford-AstraZeneca vaccine is safe, effective and has already saved thousands of lives in the UK and around the world."
Public Health England (PHE) meanwhile announced it had named a strain of the virus from India as a "Variant of Concern" after cases rose over the previous week to 520 from 202.
Most cases were clustered in Bolton, northwest England, and London, with almost half linked to foreign travel.
"The indications are that (the Indian variant) is a more transmissible variant," said Susan Hopkins, PHE's Covid-19 strategic response director.
India in recent days has seen a catastrophic surge in cases, stretching hospitals to the limit and overwhelming crematoriums.
External Affairs Minister S Jaishankar while visiting Britain for G7 meetings said Wednesday he would hold talks virtually after being exposed to possible coronavirus cases.
| Be Part of Quality Journalism |
| |
| Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast. |
| ACT NOW |
| MONTHLY | Rs 100 |
|
| | | |
| YEARLY | Rs 1000 |
|
| | | |
| LIFETIME | Rs 10000 |
|
| | | |
MENAFN07052021000215011059ID1102047708
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.